Posts

FDA Extends Capricor’s Deramiocel Decision Date to November 22

on

Capricor surges on plan to amend DMD filing after adcom setback

on

Rare Disease Drugmakers Watch FDA for Renewed Focus on Therapies

on

FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy, deramiocel

on

Capricor Shares Plunge After FDA Says DMD Therapy Lacks Efficacy Ahead of Advisory Committee Meeting

on

Capricor Sues Nippon Shinyaku and NS Pharma Over Pricing Flaw and Launch Delays for Deramiocel DMD Therapy

on

Capricor Shares Rise as FDA Sets August 2026 Decision Date for Deramiocel in Duchenne Muscular Dystrophy After Prior Rejection

on

Capricor Claims FDA Misinterpreted Efficacy Data Leading to Rejection of DMD Therapy

on

FDA Rejects Capricor's Cell Therapy for Duchenne Muscular Dystrophy

on